Kolon Group entered the FDA Phase 3 clinical trial with the arthritis treatment ‘Invossa’ in the U.S.
The world’s first degenerative arthritis gene treatment ‘Invossa™,’ developed by Kolon Group (President : Woong-yeol Lee), will get on a Phase 3 clinical trial for FDA in the U.S. This is the first case to enter a Phase 3 clinical trial in the states as a degenerative arthritis gene treatment.
I...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
